RxDoctor Payments Data

Yasser Aldurra, MD

Nephrology · Anderson, INNPI 1265747703

Payments from drug & device makers

$1,229in general payments, 2019–2025

Across 49 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$300
  • Aurinia Pharma U.S., Inc.$271
  • Otsuka America Pharmaceutical, Inc.$197
  • Amgen$133
  • Travere Therapeutics, Inc.$70
  • Bayer$60
  • plus $199 from 6 others

What the payments were for

  • Food & beverage$1,18396%
  • Education$474%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,229 in reported general payments places this provider in the 50th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$97,836
Medicare patients
264
Services billed
866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone66$79,329
FarxigaDapagliflozin Propanediol73$66,520
JardianceEmpagliflozin29$30,386
LokelmaSodium Zirconium Cyclosilicate30$20,262
Sevelamer Carbonate19$3,855
Potassium Chloride26$864
Hydralazine Hcl79$825
Valsartan30$706
Losartan Potassium83$547
Amlodipine Besylate106$460
Torsemide20$367
Tamsulosin Hcl15$344
Calcitriol12$300
Ranolazine ErRanolazine12$267
Doxazosin Mesylate14$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$300$86,782103 claims
BayerKerendia$60$79,32966 claims
Boehringer IngelheimJardiance$51$30,38629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 238 nephrology providers in Indiana.

Other nephrology in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →